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May 20091364 Letters to the Editorcatheters for dialysis, placement of inferior vena cava filters, and
femoral or brachial artery needle placement during endovascular
procedures. One may also consider incorporating the expertise of
the noninvasive vascular laboratory technicians to help with this
training. As with all techniques, repetition under an appropriate
mentor should help minimize the learning curve, minimize com-
plications, and lead to a positive training experience.
Stuart I. Myers, MD, FACS
Bryan Vascular Institute
Lincoln, Neb
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Regarding “Trends and outcomes of concurrent
carotid revascularization and coronary bypass”
The optimal management of patients with concomitant
carotid and coronary artery disease remains an enduring contro-
versy.1-3 Timaran et al1 described trends and outcomes in 27,084
concurrent carotid and coronary artery bypass grafting (CABG)
revascularization procedures during a 5-year period. More than
96% of these patients received their carotid revascularization pro-
cedure for an asymptomatic carotid stenosis. The real debate is not
about being staged or synchronous, nor about treatment type
(carotid artery stenting [CAS] vs carotid endarterectomy), but
whether treatment of asymptomatic carotid stenosis will reduce
perioperative morbidity and mortality when combined with CABG
at any stage.
In understanding the predominant cause of post-CABG
stroke, hypoperfusion and microembolization remain important
etiologic mechanisms. Patients with severe aortic disease have a
15% risk of perioperative stroke, paralleling the increased risk
caused by severe carotid stenosis. It has to be realized that 50% of
post-CABG stroke sufferers do not have carotid disease. Moreover,
60% of territorial infarctions cannot be attributed to carotid dis-
ease, confirming the multifactorial etiology of postcardiac surgery
neurologic events. Even when prophylactic carotid revasculariza-
tion would carry no additional risk at all, it can at most prevent 40%
of procedural strokes.2
Timaran concludes with suggesting that CAS may provide a
safer carotid treatment option for patients who require CABG. Van
der Heyden3 recently found a combined death/stroke rate of 1.7%
in CAS for asymptomatic carotid stenosis before surgery; however,
the overall death/stroke/myocardial infarction rate of combined
CAS/CABG still was 8.7%.
Showing that CAS can be performed with an acceptable
complication rate is not the issue. First, it must be proven that the
combination of CAS and CABG has a significant lower stroke/
death rate than CABG alone when the asymptomatic carotid artery
is left untreated. Until then, any revascularization before CABG is
unwarranted because it exposes patients to the risks of periopera-
tive stroke and myocardial infarction twice, without significantly
reducing the risk of stroke.
Gert J de Borst, MD, PhD
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University Medical Center Utrecht
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Reply
We appreciate the letter from de Borst et al and do agree that
the optimal management of patients with concomitant carotid and
coronary artery disease has not been established, particularly for
patients with asymptomatic severe carotid stenosis. We also con-
sider that there is an urgent need to establish the role of any carotid
intervention in the management of patients with asymptomatic
carotid disease who need open coronary revascularization. Unfor-
tunately, only a well-designed and conducted randomized clinical
trial could provide the answer to this important clinical problem.
Although several efforts to conduct such a trial have been made, to
our knowledge, no ongoing study is trying to resolve this issue.
The purpose of our observational, population-based, cross-
sectional study was not to define the role of carotid interventions in
the management of asymptomatic carotid stenosis in patients
undergoing coronary bypass but to provide a detailed and descrip-
tive status of the trends and outcomes of patients undergoing
combined carotid and coronary interventions in the United States.
In this regard, we have revealed that most patients undergoing
combined procedures present with asymptomatic carotid disease.
Moreover, those undergoing carotid stenting have better out-
comes compared with those undergoing carotid endarterectomy.
Whether performing carotid interventions for asymptomatic pa-
tients undergoing coronary bypass is right or wrong remains to be
elucidated, and again, was not intended to be addressed by our
study.
Although most cases of stroke during coronary bypass are
secondary to embolism, not always related to carotid disease, the
fact that up to 40% of periprocedural strokes could be prevented by
concomitant carotid interventions, as suggested by de Borst et al,
should not be ignored. In fact, it would be a sound justification for
carotid interventions for patients with asymptomatic carotid dis-
ease. Moreover, specific instances of asymptomatic carotid stenosis
that could potentially increase the risk of periprocedural stroke in
patients undergoing coronary bypass should be specifically ad-
dressed, such as patients with contralateral carotid or vertebral
artery occlusion, or both, incomplete circle of Willis, and proximal
great vessel disease. Until it is proven that the combined treatment
has or does not have a significant benefit compared with coronary
bypass alone, neither offering nor denying combined treatment
can be justified. Moreover, if combined treatment is offered for
asymptomatic carotid stenosis, carotid stenting may be a safer
option according to our results.
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